<DOC>
	<DOC>NCT00929968</DOC>
	<brief_summary>This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male and female subjects between ages of 18 to 60 in good health History of atopy for at least 2 years and positive skin prick test to ragweed allergen Exclusion criteria: History of asthma treated with corticosteroids Smokers with a smoking history of &gt; 10 pack/years or smoking in the past year History of chronic obstructive pulmonary disease Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Allergic rhinitis,</keyword>
	<keyword>atopic patients,</keyword>
	<keyword>seasonal allergy,</keyword>
	<keyword>ragweed allergy</keyword>
</DOC>